|Bid||5.99 x 47300|
|Ask||6.03 x 1300|
|Day's Range||5.92 - 6.30|
|52 Week Range||1.97 - 12.49|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.17|
A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.
Two Endo International Inc. subsidiaries have agreed to pay Oklahoma $8.75 million to resolve the state’s investigation into whether the pharmaceutical company had a role in the state’s opioid abuse crisis. The settlement agreement, under which the Endo business units admitted to no wrongdoing or liability, involved Endo Pharmaceuticals Inc. and Par Pharmaceuticals. Endo officials noted the amount it agreed to pay in connection with the settlement agreement is a "fraction" of the settlement and judgment amounts associated with other opioid manufacturers in Oklahoma.
Shares of Endo International Inc. are up 3% in afternoon trading on Friday after the company said it will pay $8.75 million to Oklahoma to settle allegations that it inappropriately promoted its opioids. As part of the settlement, the company did not admit wrongdoing. According to a news release from the Attorney General's office, Endo will not employ or contract with sales reps in Oklahoma and will not pay for direct or indirect promotion of opioids. Endo has also settled similar opioid-related lawsuits with two counties in Ohio. Endo's stock has tumbled 52% over the last year. The Health Care Select Sector SPDR exchange-traded fund is up 17%.
Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. (collectively, the "Settling Parties") have executed a Settlement Agreement with the State of Oklahoma ("Oklahoma"). The Settlement Agreement fully and finally resolves Oklahoma's investigation of the Settling Parties in connection with the opioid abuse crisis in Oklahoma and includes a release of all associated claims by Oklahoma to the Settling Parties and all of their affiliated entities and persons (collectively, the "Endo Affiliates"). In connection with the Settlement Agreement, Endo Pharmaceuticals Inc. has agreed to pay $8.75 million to Oklahoma. The Settlement Agreement includes no admission of wrongdoing, fault or liability of any kind by the Endo Affiliates. The amount paid in connection with the Settlement Agreement is a fraction of the settlement and judgment amounts associated with other opioid manufacturers in Oklahoma to date and is the result of direct engagement among Oklahoma Attorney General Mike Hunter, his staff and counsel, and the Company's senior leadership.
Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 13, 2020 at 3:30 p.m. PST.
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources. Six companies have disclosed in regulatory filings that they have received grand-jury subpoenas from the U.S. attorney's office in the Eastern District of New York, according to the report. Teva Pharmaceutical Industries Ltd. is down 8%, Mallinckrodt 5%, Amneal Pharmaceuticals Inc. 10%, and Johnson & Johnson 1%. Shares of cited wholesale drug distributors also declined, AmerisourceBergen by 3% and McKesson by 5%. In addition, shares of companies facing opioid litigation but not cited in the Journal story also dropped, with Endo International down 9% and Cardinal Health 4%. In recent weeks, the stocks of these companies have rallied as investors took the view that the possibility of global settlement that would resolve all pending and future litigation was a positive.
Shares of generic drugmakers jumped Monday as speculation mounts about a series of legal settlements potentially nearing a resolution.
Shares of generic drugmakers are up in morning trading, with Mallinckrodt leading the pack as its stock rallied 15%. Teva Pharmaceutical Industries Ltd. is up 5%, Mylan up 4% and Endo International 4%. Bloomberg reported Monday morning that sources have said Teva and other drugmakers, including Sun Pharmaceutical Industries, are in talks with the Department of Justice to resolve allegations of price-fixing in the generic drug market. Separately, SVB Leerink analysts said this week that if plans for Endo, Mallinckrodt and Teva to enter into a "global opioid settlement framework" with state attorneys general go through, likely in the fourth quarter of 2019 or the first quarter of 2020, it would be a positive for those companies. "We could also see read-through for other opioid-levered names like Endo and Mallinckrodt," the analysts wrote in a Nov. 24 note.
Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the Bank of America Merrill Lynch Leveraged Finance Conference in Boca Raton, Florida on Tuesday, December 3, 2019 at 8:50 a.m. ET.